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Abstract
Background: The standard treatment pathway for locally advanced rectal cancer is neoadjuvant chemoradiotherapy
(CRT) followed by surgery. Neoadjuvant CRT has been shown to decrease physical fitness, and this decrease is
associated with increased post-operative morbidity. Exercise training can stimulate skeletal muscle adaptations such as
increased mitochondrial content and improved oxygen uptake capacity, both of which are contributors to physical
fitness. The aims of the EMPOWER trial are to assess the effects of neoadjuvant CRT and an in-hospital exercise training
programme on physical fitness, health-related quality of life (HRQoL), and physical activity levels, as well as post-
operative morbidity and cancer staging.
Methods/Design: The EMPOWER Trial is a randomised controlled trial with a planned recruitment of 46 patients with
locally advanced rectal cancer and who are undergoing neoadjuvant CRT and surgery. Following completion of the
neoadjuvant CRT (week 0) prior to surgery, patients are randomised to an in-hospital exercise training programme
(aerobic interval training for 6 to 9 weeks) or a usual care control group (usual care and no formal exercise training).
The primary endpoint is oxygen uptake at lactate threshold ( _Vo2 at θ^L) measured using cardiopulmonary exercise
testing assessed over several time points throughout the study. Secondary endpoints include HRQoL, assessed using
semi-structured interviews and questionnaires, and physical activity levels assessed using activity monitors. Exploratory
endpoints include post-operative morbidity, assessed using the Post-Operative Morbidity Survey (POMS), and cancer
staging, assessed by using magnetic resonance tumour regression grading.
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Discussion: The EMPOWER trial is the first randomised controlled trial comparing an in-hospital exercise training group
with a usual care control group in patients with locally advanced rectal cancer. This trial will allow us to determine
whether exercise training following neoadjuvant CRT can improve physical fitness and activity levels, as well as other
important clinical outcome measures such as HRQoL and post-operative morbidity. These results will aid the design of
a large, multi-centre trial to determine whether an increase in physical fitness improves clinically relevant post-
operative outcomes.
Trial registration: ClinicalTrials.gov NCT01914068 (received: 7 June 2013). Sponsor: University Hospital Southampton
NHS Foundation Trust.
Keywords: Neoadjuvant chemoradiotherapy, Exercise training, Physical activity, Surgery, Surgical outcome
Background
The standard treatment pathway for magnetic resonance
(MR)-defined, locally advanced rectal cancer is neoadju-
vant chemoradiotherapy (CRT) followed by total mesor-
ectal excision surgery [1, 2]. Chemotherapy, combined
with radiotherapy, improves local disease control and
local recurrence for locally advanced rectal cancer [3–5].
With optimised local treatment, including neoadjuvant
CRT and surgery, local relapse rates have now been re-
duced to less than 10 % [2]. Cancer is associated with
cachexia, which, in the pre-operative period, has been
shown to influence perioperative outcome, increasing
the risk of complications, mortality and length of hos-
pital stay in major gastrointestinal surgery [6]. Chemo-
therapy has been related to skeletal muscle wasting,
oxidative stress, mitochondrial death [7] and reduced in
vivo mitochondrial function [8]. Furthermore, cancer
treatment has been linked to decreased physical fitness
levels, which appear to be related to the type of treatment;
that is, physical fitness is lower in those receiving surgery
and radiotherapy in combination with chemotherapy than
in those who receive radiotherapy or surgery alone [9].
Neoadjuvant CRT has been shown to be associated with a
decrease in objectively measured physical fitness, as mea-
sured by cardiopulmonary exercise testing (CPET) in
those with locally advanced rectal cancer [10]. This de-
crease in physical fitness was in turn shown to be associ-
ated with increased short-term post-operative morbidity
[10]. Moreover, a decrease in physical fitness has also been
shown in a group of upper gastrointestinal cancer patients
following neoadjuvant chemotherapy [11]. In this case, the
change was associated with 1-year mortality [11].
CPET is a good pre-operative risk assessment tool as
it provides an objective global assessment of the integra-
tive responses of the pulmonary, cardiovascular and
musculoskeletal systems rather than evaluating the func-
tion of individual organ systems in isolation [12]. Fur-
thermore, as a dynamic assessment, CPET provides
more insight than a resting test into the response to
physiological stress. The perioperative period is a time of
physiological stress as the surgical stress response
increases the metabolic rate, and consequently, tissue
oxygen demand rises. By detecting abnormal exercise
capacity and, consequently, reduced physiological re-
serve, CPET identifies patients at increased risk of com-
plications and mortality. CPET is increasingly being
used preoperatively to identify patients at high risk of
perioperative morbidity and mortality [13–15].
Exercise training can stimulate skeletal muscle adapta-
tions such as increased mitochondrial content and im-
proved oxygen uptake capacity [16], both of which are
contributors to physical fitness and could possibly re-
duce the adverse effects of cancer treatment. In 2013,
Jones and Aflano [17] reported a series of observational
studies that suggest higher levels of exercise may be asso-
ciated with an improved prognosis in patients with solid
tumours. Physical fitness is a modifiable prognosticator,
and women with breast cancer who exercise at moderate
intensity, 30 minutes or more per day on 5 days or more
per week have been reported to have a lower risk of death
[18]. Furthermore, women who were physically active fol-
lowing diagnosis of non-metastatic colorectal cancer have
been shown to have a significantly lower risk of colorectal
cancer–specific death or death from any cause [19]. Our
group (Fit-4-Surgery) has previously shown in a non-
randomised study that a 6-week moderate to severe inten-
sity, interval exercise training programme, following neo-
adjuvant CRT and prior to surgery in patients with locally
advanced rectal cancer resulted in a clinically relevant in-
crease in physical fitness [20] and HRQoL [21].
In this manuscript, we describe the design of a parallel
group randomised controlled multi-centre trial compar-
ing an in-hospital exercise training programme to a
usual care control group in patients undergoing neo-
adjuvant CRT and elective surgery for locally ad-
vanced rectal cancer. To the best of our knowledge,
the EMPOWER trial is the first RCT of such an
intervention in a neoadjuvant setting.
Aims
The aims of this study are to evaluate the following
hypotheses:
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Primary hypothesis
A 9-week, in-hospital, exercise training programme
compared with a usual care control group (usual care;
no formal exercise training) will result in a clinically sig-
nificant difference in oxygen uptake at lactate threshold
( _Vo2 at θ^L ; 2.0 mL.kg
-1.min−1) assessed using CPET,
following neoadjuvant CRT prior to elective cancer
surgery.
Secondary hypothesis
a) An in-hospital exercise training programme
compared with a usual care control group (usual
care; no formal exercise training) will result in an
improvement in psychological health benefits as
assessed using semi-structured interviews and
questionnaires such as the EORTC QLQ-30 and
EQ-5D following neoadjuvant CRT prior to cancer
surgery.
b) Neoadjuvant CRT will result in a reduction in _Vo2
at θ^L as assessed using CPET.
Exploratory hypotheses
A 9-week in-hospital exercise training programme com-
pared with a usual care control group (usual care; no for-
mal exercise training) will be associated with 1) greater
physical activity, assessed using SenseWear accelerometer,
following neoadjuvant CRT prior to cancer surgery;
2) lower day 5 surgical morbidity (using POMS); and
3) improved Magnetic Resonance (MR)-defined local
rectal cancer staging assessed using the TNM classifica-
tion system (tumour, nodes, metastasis) and tumour re-
gression grading (mrTRG).
Methods/Design
Study design
The EMPOWER Trial is a parallel group randomised
controlled trial in locally advanced rectal cancer patients
undergoing both neoadjuvant CRT and elective surgery.
The trial is funded by the National Institute for Health
Research - Research for Patient Benefit Programme (PB-
PG-0711-25093), approved by North West Centre for
Research Ethics Committees (13/NW/0259) and regis-
tered with clinicaltrials.gov (NCT01914068).
Recruiting hospitals
Five NHS hospitals are currently recruiting to the trial:
the University Hospital Southampton (UHS) NHS
Foundation Trust, Aintree University Hospitals NHS
Foundation Trust, Royal Hampshire County Hospital,
South Tees Hospitals NHS Foundation Trust and Royal
Bournemouth Christchurch Hospitals.
Participants
Eligibility criteria for inclusion at cancer diagnosis include
the following: age ≥ 18 years, with MR-defined, locally
advanced (circumferential resection margin threatened),
resectable rectal cancer (≥ T2N+M0), undergoing stan-
dardised neoadjuvant CRT; with no distant radiological
defined metastasis. Exclusion criteria include the follow-
ing: inability to give informed consent, non-resectable
disease, distant metastasis, inability to perform CPET
or bicycle exercise, and patients who declined surgery
or neoadjuvant CRT or who received non-standard
neoadjuvant CRT. Figure 1 provides an algorithm of
the clinical pathway and the complete series of as-
sessments for the duration of the trial.
Recruitment and randomisation
The EMPOWER trial is currently recruiting (start date is
August 2013; end date is December 2015). All poten-
tially eligible patients are being identified at multi-
disciplinary meetings and approached with written in-
formation about the trial at the oncology/surgical out-
patient appointment. Patients are contacted by
telephone to provide additional information about the
trial and to confirm their eligibility. If the patient
chooses to participate in this trial, the first research
visit is organised where written informed consent is
obtained and all baseline measurements are under-
taken. Following neoadjuvant CRT (week 0), patients
are allocated to the in-hospital exercise training group
or usual care control group. Patients are randomised (1:1)
to either an in-hospital exercise training programme or
usual care control group using the Trans European
Network for patient randomisation in clinical trials system
(TENAELA System).
Interventions
Usual care control group
The usual care control group (no formal exercise train-
ing) receive routine care throughout their cancer path-
way from diagnosis to surgical resection. No specific
advice about exercise training is offered.
Exercise intervention group
The exercise training programme was designed to im-
prove physical fitness in the time interval between end
of neoadjuvant CRT and surgery. Exercise training
begins on the first week following completion of neoad-
juvant CRT, and the patients exercise in pairs for cama-
raderie. The exercise training programme is described
below.
Exercise training protocol
The delivery of the exercise training programme is de-
scribed using the FITT principle (frequency, intensity,
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time and type of exercise training (American College of
Sports Science, 2009)) detailed below.
Exercise training frequency
Patients are requested to attend three in-hospital exer-
cise training sessions per week for 6 to 9 weeks
(dependent on the time interval between neoadjuvant
CRT and surgery at each hospital).
Exercise training intensity
The exercise training is an aerobic interval exercise
training programme incorporating moderate and severe
intensities. Exercise training intensities are derived from
each individual CPET derived at Week 0 (immediately
post-CRT). Moderate-intensity exercise is at a power
output equivalent to 80 % of the oxygen uptake at lactate
threshold ( _Vo2 at θ^L ). Severe-intensity exercise is at a
power output half-way between _Vo2 at θ^L and _Vo2 at
peak (termed 50%Δ). Algebraically, this is calculated as
follows:
Moderate-intensity exercise: (Work load at _Vo2 at
θ^L −2 3= of work ramp) × 80 %
Severe-intensity exercise: ((Work load at _Vo2 at Peak-
Work load at _Vo2 at θ^L −2 3= of work ramp) × 50 %) +
Work load at _Vo2 at θ^L.
Fig. 1 The EMPOWER trial algorithm presented illustrates the patient pathway and the time points of assessments and intervention as part of
the trial
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Each exercise session included a 5-minute warm-up
and cool-down using unloaded pedalling. Exercise train-
ing intensities are responsive to each CPET (informed
by measured work rates at _Vo2 at θ^L and _Vo2 Peak at
Weeks 3 and 6) during the exercise programme and are
derived and reported by two assessors. The absolute
power output for subsequent training sessions are ad-
justed according to the outcome of the CPET.
Exercise training time
The first two training sessions involve 30 minutes of ex-
ercise which increases to 40 minutes per session there-
after. In the first week of training, patients perform the
interval exercise training protocol for 20 minutes with a
5-minute warm-up and cool down. The interval exercise
training phase includes four repeated bouts of moderate
to severe intensity. Following week 1, the time of each
exercise training session increases to 30 minutes with a
5-minute warm-up and cool down. The interval exercise
training phase includes six repeated bouts of moderate-
to severe-intensity intervals.
Exercise training type
The exercise training programme is conducted on a
computer-controlled, electromagnetically braked, cycle
ergometer (Optibike Ergoselect 200; Ergoline, GmbH,
Bitz, Germany) (see Fig. 2). Heart rate is continuously
recorded from the R-R interval (Polar FT7, Warwick,
UK). The training programme is preloaded on to a chip-
and-pin card that executes the interval intensities auto-
matically onto the screen displayed on the cycle ergom-
eter (see Fig. 3).
Outcome measurements
All patients undergo a series of outcome measure assess-
ments throughout the period of the trial: baseline (pre-
neoadjuvant CRT), mid-neoadjuvant CRT and at several
time points following completion of the neoadjuvant
CRT (weeks 0, 3, 6 and 9) prior to surgery (surgery gen-
erally takes place between weeks 6 and 9, depending on
the hospital). In UHS only, based on the clinical
pathway, some patients are treated with neoadjuvant
chemotherapy (four cycles) followed by neoadjuvant
CRT. In this instance, an additional research visit is
scheduled halfway between the completion of chemo-
therapy and commencing CRT). The outcome mea-
sures used in the EMPOWER trial are summarised in
Table 1.
Primary outcome
Physical fitness
CPET is used to assess physical fitness over a series
of time points (which vary in each hospital depending
on the cancer treatment and time interval between
CRT and surgery): baseline (pre-neoadjuvant CRT);
mid chemotherapy-CRT (in UHS only); and post-
neoadjuvant CRT (week 0), week 3, week 6 and week 9.
All CPETs are performed in the hospital by trained and
experienced staff. Every effort is made to coordinate re-
search visits with other clinical appointments. Each CPET
is conducted at a similar time of day. Participants are
asked to refrain from caffeine and strenuous exercise
prior to the test. All CPETs are performed using an
electromagnetically-braked cycle ergometer (Ergoline
2000), a 12-lead ECG, non-invasive blood pressure
measurement and pulse oximetry, and a metabolic
cart (Geratherm Respiratory GmbH, Love Medical
Ltd). The incremental rise in work rate is pre-
determined using the equation derived by Wasserman
and colleagues [22] in which the same work-rate
protocol is used for each CPET. This is done in an
Fig. 2 Exercise training cycle ergometers (Optibike Ergoselect 200;
Ergoline, GmbH, Germany)
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objective manner aiming for a test duration between
8 and 12 minutes. The ramp protocol equation is as
follows:
_Vo2 unloaded ml:min−1ð Þ ¼ 150þ 6 weight kgð Þð Þ
_Vo2 at Peak ml:min−1ð ÞMen ¼ height cmð Þ−age yð Þ½   20
_Vo2 at Peak ml:min−1ð ÞWomen ¼ height cmð Þ−age yð Þ½   14
Work Rate increment W:min−1ð Þ ¼ Peak _Vo2− _Vo2 UnloadedÞ=100
Each participant receive instructions on how to rate
the Borg Scale of perceived exertion (Scale 0 to 10),
which is a subjective rating of breathlessness and for leg
fatigue (assessed every 2 minutes during the test). Add-
itionally, blood pressure is recorded every 2 minutes
during the test. Saddle height is measured and recorded
at the first CPET and remains constant for all other
CPETs. Once the patient is comfortable on the bike, the
mask is fitted. The patients are asked to perform an in-
cremental ramp test to the limit of tolerance and to
maintain a cycling cadence at 55–65 revolutions per mi-
nute (rpm) throughout the test. CPET allows for the der-
ivation of lactate threshold using the modified V-Slope
method [23, 24]. The modified V-Slope method identi-
fies the lactate threshold as the tangential breakpoint in
the rate of change of _V CO2 relative to _Vo2 (oxygen up-
take – carbon dioxide output) from the line of unity
(‘line of one’) during the incremental stage of the exer-
cise test. The V-slope methods depend solely on the
physicochemical reaction of hydrogen ions with bicar-
bonate, and as such, the occurrence of the breakpoint is
independent of the chemoreceptor sensitivity and the
ventilatory response to exercise [23]. The inter-observer
variability for experienced clinicians is very acceptable
[25]. Two independent physiological data assessors are
blind to group allocation and are independent to the
intervention. The multi-disciplinary team caring for the
patients are not provided with any information regarding
outcome measures.
Secondary outcome
Health-related quality of life (HRQoL)
HRQoL is assessed in two ways: 1) Semi-structured in-
terviews are conducted at week 0 (following neoadjuvant
CRT) and at weeks 6 to 9 (prior to surgery) to explore
the patients’ perceptions of quality of life, which allows
the patients to focus on personal accounts of their
HRQoL within a specific context (for example, exercise
participation and active cancer treatment). 2) HRQoL
questionnaires are administered over several time points
during the study: baseline (pre-neoadjuvant CRT), mid-
chemotherapy CRT (in UHS only), mid-neoadjuvant
CRT, post-neoadjuvant CRT (week 0), week 3, week 6,
week 9 and 30 days post-surgery. The two question-
naires administered at these time points are the EORTC
QLQ-30 and EQ-5D. EORTC QLQ-30 is specific to can-
cer patients and is validated to assess generic aspects of
HRQoL. EQ-5D is a simple descriptive profile and a sin-
gle index value for health status.
Exploratory outcome measure
Physical activity
Daily physical activity is measured over three consecu-
tive days and nights at a series of time points: baseline
(pre-neoadjuvant CRT), mid-chemotherapy CRT (in
UHS only), post-neoadjuvant CRT (week 0), week 3,
week 6 and week 9. Physical activity is measured using a
multi-sensory accelerometer ((SenseWear Pro® armband
(Model MF-SW, display model DD100); BodyMedia,
Inc., Pittsburgh, PA, USA)), which records daily move-
ments, including total energy expenditure, physical
activity duration, lying-down time, active energy expend-
iture, number of steps, sleep duration, total energy ex-
penditure, degree of physical activity, average metabolic
equivalent threshold (MET), duration of sensor on body,
sleep efficiency, and physical activity level (PAL, which is
the ratio of estimated daily energy expenditure to esti-
mated basal metabolic rate).
Post-operative morbidity survey (POMS)
Post-operative outcomes will be objectively recorded
using POMS on days 3, 5, 8 and 15. The POMS is a vali-
dated 18-item tool that addresses nine domains of mor-
bidity relevant to the post-surgical patient: pulmonary,
infection, renal, gastrointestinal, cardiovascular, neuro-
logical, wound complications, haematological and pain
[26, 27]. For each domain, either the presence or ab-
sence of morbidity is recorded on the basis of precisely
defined clinical criteria.
Fig. 3 Screen shot of the display on the exercise ergometer at the
end of a 40-minute exercise session. This shows power (W) and heart
rate (beats.min-1) on the y-axis versus time (min) on the x-axis. The
square wave pattern on the background is the preloaded exercise
training programme. The sinusoidal pattern on the foreground is the
variation in heart rate with the different training intensities recorded
over time
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Table 1 Outcomes and assessment measures used in the EMPOWER trial
Outcomes Assessment measure Pre CRT Mid chemo-CRT Mid
CRT
Week 0 Week 3 Week 6 Week 9 Day 3
post-surgery
Day 5
post-surgery
Day 8
post-surgery
Day 15
post-surgery
6 Weeks
post-surgery
Primary endpoint
Oxygen uptake at
lactate threshold
CPET X UHS only X X X X
Secondary endpoint
Health-related
quality of life
Questionnaires:
EORTC QLQ-30,
EQ-5D
X UHS only X X X X X X
Semi-structured
interviews
X X
Physical activity SenseWear
accelerometer
X UHS only X X X X X
Exploratory endpoint
Post-operative
morbidity
POMS X X X X
Cancer staging MR pelvis mrTRG X X
X
Abbreviations: CRT chemoradiotherapy, CPET cardiopulmonary exercise test, UHS University Hospital Southampton, POMS Post- operative morbidity score, mrTRG magnetic resonance tumour regression grade,
MR magnetic resonance
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Cancer staging
Cancer down-staging will be assessed using the TNM
classification. Rectal cancer staging will be assessed
using an abdominal-pelvic CT scan and pelvic MRI scan
pre-neoadjuvant CRT and at 9 weeks following com-
pletion of the neoadjuvant CRT. The TNM classifica-
tion of malignant tumours is a cancer staging
notation system that gives codes to describe the stage
of a solid tumour [28].
Safety
All adverse events are recorded in the relevant case re-
port form. Adverse events during CPET are reported to
the chief investigator, and adverse effects during exercise
training (pain and muscle soreness) are recorded in the
relevant case report form by the research physiologist/
nurse. Fatal or life-threatening serious adverse events
(SAEs) are reported within 24 hours of the local site be-
coming aware of the event. The SAE form documents
the nature of the event, date of onset, severity, corrective
therapies given, outcome and causality (that is, unre-
lated, unlikely, possibly, probably, or definitely). Ques-
tions concerning adverse event reporting are directed to
the chief investigator in the first instance.
Data analysis
Sample size calculation
A sample of 46 patients is required to detect a difference
between groups of 2.0 mL.kg-1.min−1 _Vo2 at θ^L using a
two-sample t-test at the 5 % significance level with 90 %
power. This is based on a standard deviation of the
change in _Vo2 at θ^L values of 1.8 ml.kg
−1·min−1 and is
inflated to allow for 20 % patient drop-out [29]. This
estimate was calculated using the sampsi function in
Stata/IC 12.0.
Procedures for data checking and entering
Data will be double data entered, and data validation will
take place according to the procedures set out in the
data management plan and data validation plan. Prior to
any statistical analysis, all variables will be checked for
the number of missing values, impossible values and im-
probable values. Impossible and improbable values will
be defined by clinical opinion. Improbable values will
also include values that are outside three standard devia-
tions of the mean value. Any questions regarding the
data will go back to the data manager. Descriptive statis-
tics will be calculated for all variables, and distributional
assumptions will be checked.
Statistical analyses
Descriptive analyses will be carried out to summarise pa-
tient characteristics. Continuous variables will be reported
as mean (range), mean (SD) or median and inter-quartile
range (IQR), depending on distribution, and categorical
variables as frequency (%). The effect of neoadjuvant CRT
and the exercise intervention on physical fitness will be
assessed using a two-sample t-test, and a 95 % confidence
interval on the mean difference between the two groups
will be presented. In order to assess the sensitivity of re-
sults to covariates, a further ‘adjusted’ effect will be calcu-
lated using linear regression where up to three candidate
covariates will be identified [30]. Basic exploratory analysis
of physical fitness at each time-point will be undertaken
to investigate the longitudinal response of fitness. Linear
mixed modelling will then be employed to compare more
formally the fitness at each time-point. Confirmatory ana-
lysis using ordinal regression will be used to assess the
suitability of the t-test for comparing the HRQoL between
the groups. The effect of an in-hospital exercise training
programme on physical activity will be analysed in the
same way as physical fitness. The presence/absence of
post-operative morbidity as defined by a POMS score > 0
will be compared between groups by calculating the rela-
tive risk with a 95 % confidence interval. Cancer staging
will be reported as tumour, node metastasis version 5
(TNM) staging, Response Evaluation Criteria in Solid
Tumours (RECIST) and MR tumour regression grading
(mrTRG) criteria. Pathological outcomes will be graded
according to the pathological tumour regression grading
(TRG) and TNM. Univariate logistic regression analysis
will be used to analyse the association between demo-
graphic variables (patient age and sex), MRI parameters
and pathologic tumour response. This will enable the cal-
culation of odds ratios (OR) for the probability of an un-
favourable pathological outcome. Analyses of sensitivity,
specificity, positive and negative likelihood ratios will be
performed.
The Standard Protocol Items-Recommendations for
Interventional Trials (SPIRIT) table provides an over-
view of the study conduct, review, reporting and inter-
pretation and is presented in Table 2. The final report
will follow the Consolidated Standards of Reporting Trials
(CONSORT), as well as the Template for Intervention
Description and Replication (TIDieR).
Discussion
The cancer treatment pathway for locally advanced
rectal cancer carries some risk. Neoadjuvant CRT and
surgery are associated with side effects and post-
operative complications [1, 31]. The level of risk associ-
ated with surgery has been examined in a recent
European Surgical Outcome Study [32], which reported
a mortality rate (3.6 %) that was substantially higher
than expected. In the United Kingdom, interest is grow-
ing in the use of CPET to objectively risk stratify fitness
prior to major surgery in order to better inform a
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Table 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Table
Administrative details
Title A multi-centre, parallel group randomised controlled trial, in locally advanced rectal cancer
patients investigating the effects of neoadjuvant chemoradiotherapy and an in-hospital exercise
training programme on physical fitness and quality of life in locally advanced rectal cancer
patients (The EMPOWER Trial).
Trial registration ClinicalTrials.gov: NCT01914068 (received: 7 June 2013)
Protocol version 16/01/2015, version 4
Funding National Institute for Health Research (NIHR) for Patient Benefit Programme (PB-PG-0711-25093).
Roles and responsibilities MPWG, SJ, MAW, GJK and HBR conceived the study. LL, MAW, GJK, HBR, SMB, TC, PC, CB, DHP,
MGM, MPWG and SJ contributed to the study design. LL drafted the manuscript, which
underwent revision by all other authors. All authors read and approved the final manuscript.
Sponsor contact information Dr Mikayala King, Research & Development Department, University Hospital Southampton NHS
Foundation Trust.
Email: Mikayla.King@uhs.nhs.uk
Sponsor and funder The sponsor and funding course had no role in the design of the study and will not have any
role during its execution, analyses, interpretation of the data or decision to submit results.
Committees The chief investigator (CI: Dr Jack) has overall conduct of the study. The study co-ordinator
(SC: Ms Loughney) ensures day-to-day management of the study while working in close
contact with the LA Prof. Grocott. The SC is the first point of contact for enquiries from all
hospital sites. The SC and CI ensure milestones are achieved in a timely manner.
The study management group (SMG) is constituted by the CI and all co-investigators. This
group is responsible for the strategic management of the study. The SMG maintain quarterly
teleconferences and meet face-to-face twice per year (minimum of six meetings). The SMG is
chaired by the CI. Local study management groups (LSMGs) comprise participating local
investigators, data manager, specialist nurses, clinicians and the local patient representative.
Each LSMG is chaired by the local study lead. The LSMGs meet monthly, and the CI will call
additional ad hoc meetings. Each hospital has its own ICH-GCP standard with random audit
of documents.
Introduction
Background and rationale The standard treatment pathway for locally advanced rectal cancer is neoadjuvant
chemoradiotherapy (CRT) followed by surgery. Neoadjuvant CRT has been shown to decrease
physical fitness, and this decrease is associated with increased post-operative morbidity.
Exercise training can stimulate skeletal muscle adaptations such as increased mitochondrial
content and improved oxygen uptake capacity, both of which contribute to physical fitness.
The aims of the EMPOWER trial are to assess the effects of neoadjuvant CRT and an in-hospital
exercise training programme on physical fitness, health-related quality of life (HRQoL), and
activity levels, as well as post-operative morbidity and cancer staging.
Comparators The usual care control group (usual care – no formal exercise training) receive routine care
throughout their cancer pathway from diagnosis to surgical resection. No specific advice about
exercise training is offered.
Objectives The aims of this study were to evaluate the following hypotheses:
Primary hypothesis: A 9-week in-hospital exercise training programme compared with a usual
care control group (usual care - no formal exercise training) will result in a clinically significant
difference in oxygen uptake at lactate threshold ( _Vo2 at θ^L ; 2.0 mL.kg-1.min−1) assessed using
CPET, following neoadjuvant CRT prior to elective cancer surgery.
Secondary hypothesis: a) An in-hospital exercise training programme compared with a usual
care control group (usual care - no formal exercise training) will result in an improvement in
psychological health benefits assessed using semi-structured interviews and questionnaires
such as EORTC QLQ-30 and EQ-5D, following neoadjuvant CRT prior to cancer surgery.
b) Neoadjuvant cancer treatment will result in a reduction in _Vo2 at θ^L assessed using CPET.
Exploratory hypotheses: A 9-week in-hospital exercise training programme compared with a
usual care control group (usual care - no formal exercise training) will be associated with 1) a
change in physical activity, assessed using SenseWear accelerometer, following neoadjuvant
CRT prior to cancer surgery; 2) a change in day 5 surgical morbidity (using POMS) and 3) a
change in magnetic resonance (MR)-defined local rectal cancer staging assessed using the
TNM classification system (tumour, nodes, metastasis) and tumour regression grading (mrTRG).
Trial design Parallel group randomised controlled multi-centre trial.
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Table 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Table (Continued)
Methods: Participants, interventions, and outcomes
Study setting In-hospital. Hospitals include: the University Hospital Southampton NHS Foundation Trust;
Aintree University Hospitals NHS Foundation Trust; Royal Hampshire County Hospital,
South Tees Hospitals NHS Foundation Trust; and Royal Bournemouth Christchurch Hospitals.
Eligibility criteria Eligibility criteria for inclusion at cancer diagnosis include the following: age ≥18 years, with
MR-defined locally advanced (circumferential resection margin threatened) resectable rectal
cancer (≥T2N +M0), undergoing standardised neoadjuvant CRT, and with no distant radiological
defined metastasis. Exclusion criteria include the following: inability to give informed consent,
non-resectable disease, distant metastasis, inability to perform CPET or bicycle exercise, and
patients who declined surgery or neoadjuvant CRT, or who received non-standard neoadjuvant
CRT.
Interventions Patients are randomised (1:1) to either an in-hospital exercise training programme or usual care
control group following neoadjuvant CRT (week 0).
Exercise intervention group
The exercise training programme was designed to improve physical fitness in the time interval
between the end of neoadjuvant CRT and surgery. Exercise training begins on the first week
following completion of the neoadjuvant CRT with patients exercising in pairs for camaraderie.
The exercise training programme is described below.
Outcomes Following completion of neoadjuvant CRT (week 0) prior to surgery, patients are randomised to
an in-hospital exercise-training programme (aerobic interval training for 6 to 9 weeks) or a usual
care control group (usual care -no formal exercise training). The primary endpoint is oxygen
uptake at lactate threshold ( _Vo2 at θ^L) measured using cardiopulmonary exercise testing
assessed over several time points throughout the study. Secondary endpoints include HRQoL,
assessed using semi structured interviews and questionnaires, and physical activity levels
assessed using activity monitors. Exploratory endpoints include post-operative morbidity,
assessed using the Post-Operative Morbidity Survey (POMS), and cancer staging, assessed by
using magnetic resonance tumour regression grading.
Participant timeline CPET is used to assess physical fitness over a series of time points (which vary in each hospital
dependent on cancer treatment and time interval between CRT – surgery): baseline
(pre-neoadjuvant CRT), mid-chemotherapy-CRT, post-neoadjuvant CRT (week 0), week 3, week 6
and week 9. HRQoL is assessed in two ways: 1) Semi-structured interviews are conducted at
week 0 (following neoadjuvant CRT) and at week 6 to 9 (prior to surgery) to explore patients’
perceptions of quality of life, which allows the patients to focus on personal accounts of their
HRQoL within a specific context (for example, exercise participation and active cancer treatment);
2) HRQoL questionnaires are administered over several time points during the study: baseline
(pre-neoadjuvant CRT), mid-chemotherapy CRT (in UHS only), mid neoadjuvant CRT, post
neoadjuvant CRT (week 0), week 3, week 6, week 9 and 30 days post-surgery. Daily physical
activity is measured over three consecutive days and nights at a series of time points; baseline
(pre neoadjuvant CRT), mid-chemotherapy-CRT (in UHS only), post-neoadjuvant CRT (week 0),
week 3, week 6 and week 9. Physical activity is measured using a multi-sensory accelerometer
((SenseWear Pro® armband (Model MF-SW, display model DD100); BodyMedia, Inc., Pittsburgh,
PA, USA)) (see Table 1).
Sample size A sample of 46 patients is required to detect a difference between groups of 2.0 mL.kg-1.min−1 _Vo2
at θ^L using a two-sample t-test at the 5 % significance level with 90 % power. This is based on a
standard deviation of the change in _Vo2 at θ^L values of 1.8 ml.kg−1.min−1 and is inflated to allow
for 20 % patient drop-out. This estimate was calculated using the sampsi function in Stata/IC 12.0.
Recruitment If recruitment is not achieving the target sample size, additional hospitals will be opened to
recruit participants.
Methods: Assignment of interventions
Allocation:
Sequence generation Patients are randomised (1:1) to either an in-hospital exercise training programme or usual care
control group using the Trans European Network for patient randomisation in clinical trials
system (TENAELA System).
Implementation Randomisation will be generated by the research nurse/Physiologist at each hospital site.
Blinding Two independent physiological data assessors are blind to group allocation and are independent
to the intervention.
Methods: Data collection, management, and analysis
Data collection methods For the primary and secondary outcomes, CPET measures changes in physical fitness.
Questionnaires and semi-structured interviews will assess changes in HRQoL and physical activity
monitoring measures changes in activity levels. Other outcomes are listed in Table 1: Outcomes
and assessment measures used in the EMPOWER trial.
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Data management Data will be double data entered, and data validation will take place according to the procedures
set out in the data management plan and data validation plan. Prior to any statistical analysis, all
variables will be checked for number of missing values, impossible and improbable values.
Impossible and improbable values will be defined by clinical opinion. Improbable values will also
include values that are outside three standard deviations of the mean value. Any questions
regarding the data will go back to the data manager. Descriptive statistics will be calculated for
all variables and distributional assumptions checked.
Statistical methods The effect of neoadjuvant CRT and the exercise intervention on physical fitness will be assessed
using a two-sample t-test, and a 95 % confidence interval on the mean difference between the
two groups will be presented. In order to assess the sensitivity of results to covariates, a further
‘adjusted’ effect will be calculated using linear regression where up to three candidate covariates
will be identified. Basic exploratory analysis of physical fitness at each time-point will be
undertaken to investigate the longitudinal response of fitness. Linear mixed modelling will then
be employed to compare more formally the fitness at each time-point. Confirmatory analysis
using ordinal regression will be used to assess the suitability of the t-test for comparing HRQoL
between groups. The effect of an in-hospital exercise training programme on physical activity
will be analysed in the same way as physical fitness. The presence/absence of post-operative
morbidity as defined by a POMS score > 0 will be compared between groups by calculating the
relative risk with a 95 % confidence interval. Cancer staging will be reported as tumour, node
metastasis version 5 (TNM) staging, Response Evaluation Criteria in Solid Tumours (RECIST) and
MR tumour regression grading (mrTRG) criteria. Pathological outcomes will be graded according
to the pathological tumour regression grading (TRG) and TNM). Univariate logistic regression
analysis will be used to analyse the association between demographic variables (patient age
and sex), MRI parameters and pathologic tumour response This enabled calculation of odds
ratios (OR) for the probability of an unfavourable pathological outcome. Analyses of sensitivity,
specificity, positive and negative likelihood ratios will be performed.
Methods: Monitoring
Data monitoring Data is monitored after the first complete patient at each site to ensure high quality data.
Additionally, quality checks are carried out on all CPET’s. An interim analysis will be conducted
at the half-way point of the trial.
Harms All adverse events are recorded in the relevant case report form; adverse events during CPET are
reported to the chief investigator and adverse effects during exercise training (pain and muscle
soreness) are recorded in the relevant case report form by the research physiologist/nurse. Fatal
or life-threatening serious adverse events (SAEs) are reported within 24 hours of the local site
becoming aware of the event. The SAE form documents the nature of the event, date of onset,
severity, corrective therapies given, outcome and causality (that is, unrelated, unlikely, possibly,
probably, definitely). Any questions concerning adverse event reporting are directed to the chief
investigator in the first instance.
Ethics and dissemination
Research ethics approval Ethical approval: North West Centre for Research Ethics Committees (13/NW/0259, Date: May 2013)
Protocol amendments Protocol amendments will be agreed and approved by the North West Centre for Research
Ethics Committees.
Consent or assent All potentially eligible patients are identified at multi-disciplinary meetings and approached with
written information about the trial at the oncology/surgical outpatient appointment. Patients are
contacted by telephone to provide additional information about the trial and to confirm their
eligibility. If the patient chooses to participate in this trial, the first research visit is organised
where written informed consent is obtained and all baseline measurements are undertaken.
Confidentiality Data will be entered with all direct patient identifiers removed, patients will be identified by
study codes. All physiological data are held in an encrypted format. All data will be stored in a
secured locked room.
Declaration of interests The authors declare that they have no competing interests.
Access to data Only members of the clinical and research team will have access to patient records.
Dissemination policy Dissemination of findings to the academic community will be led by the lead applicant guided
by the SMG. Dissemination of research findings to patients and the general public will be led
by the patient representatives guided by the SMG. The SMG will give public engagement
interviews/talks in support of the patient representatives. Active patient involvement will be
sought for radio and television interviews, together with issuing of patient statements that can
be used at local hospital level to raise awareness regarding prehabilitation and an active life-style
in general. The SMG have extensive experience of disseminating medical information to the
public and the media, due to the involvement of Professor Grocott as founder member of the
Improving Surgical Outcomes Group. He is also involved in the Caudwell Xtreme Everest project,
which was widely publicised. The group delivered more than 100 lectures to schools, colleges
and in other public forums.
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discussion of risk within the collaborative decision mak-
ing process and to aid personalised perioperative patient
care [33]. Physical fitness is an important element of
post-operative outcome, and exercise training has the
ability to improve clinically important CPET variables
[34]. The EMPOWER trial will be the first RCT to inves-
tigate the effects of neoadjuvant CRT and an in-hospital
exercise training programme on physical fitness, HRQoL
and physical activity, as well as post-operative morbidity
and cancer staging.
Pre-operative physical fitness is associated with post-
operative outcome, with the less fit patients having a
greater prevalence of adverse outcomes. Neoadjuvant
CRT decreases physical fitness in this patient group, and
this decrease is associated with increased post-operative
complications [10]. The EMPOWER trial will evaluate
the effect of the intervention on physical fitness,
HRQoL, physical activity and positive behavioural re-
sponses to exercise in the short term. Additionally, the
EMPOWER intervention has the potential to effect a
long-term benefit because an improvement in periopera-
tive fitness might translate into better post-operative
outcomes (longer survival and fewer post-operative com-
plications), cancer down-staging and less demand on
hospital resources (reduction in patient length of stay,
reduced demand for post-operative high dependency
care and associated health economic benefits). The
EMPOWER trial will also yield an effect size which can
be used to power a further definitive randomised con-
trolled trial and to investigate the association of change
in pre-operative physical fitness with exercise and post-
operative complications.
Strengths of the EMPOWER trial include the study
design with parallel group 1:1 randomisation; the two in-
dependent physiological data assessors who are blind to
group allocation and independent of the intervention;
and that the multi-disciplinary team caring for the pa-
tients are not provided with any information regarding
predictive measures (for example, CPET variables) en-
suring a low risk of confounding by indication [35]. Also,
patients are recruited consecutively, all of whom are
scheduled for a pre-defined CRT regime and have a
homogenous MR-defined rectal cancer staging. Further-
more, the statisticians conducting the analyses are blind
to the group allocation until after the analysis is
complete. Data are handled using a double entry data
system, and impossible or improbable values are ques-
tioned. The novelty of the in-hospital exercise training
programme in this patient cohort and the statistical ana-
lyses used are also worth highlighting.
Conclusion
In summary, the EMPOWER trial will investigate
changes in objectively measured physical fitness and
HRQoL with a structured pre-operative exercise training
programme. Furthermore, it will also explore changes in
physical activity with exercise and any impact on post-
operative outcome measures. Additionally, it may inform
the development of generalisable exercise programmes
for major surgical patients who are identified as high
risk (lower physical fitness levels) following cancer
treatment.
Trial status
The trial started patient enrolment in August 2013 and
is expected to be completed by the end of December
2015.
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